SCHEMBL1743044

SCHEMBL1743044

Clc1ccc(-c2cccnc2)nn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.56
MAPT P10636 4/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.52
CYP3A4 P08684 3/20 0.52
CYP1A2 P05177 2/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
GAA P10253 1/20 0.49
CYP19A1 P11511 3/20 0.48
METAP2 P50579 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368099 1.00 CYP2A6 (0.56) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL31556857 0.78 ATM (0.38) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL21623948 0.78 ATM (0.38) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL30402035 0.77 RAB9A (0.50) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL240423 0.77 RAB9A (0.50) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL11252868 0.77 CYP2A6 (0.52) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL29818023 0.77 CYP2A6 (0.55) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL16826055 0.77 CYP2A6 (0.55) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL13750550 0.77 CYP2A6 (0.58) CYP2A6MAPTMEN1KMT2AALDH1A1
SCHEMBL30948178 0.77 MAPT (0.49) CYP2A6MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115872976-B Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of pharmaceutical composition 中国药科大学 2024-05-14 CN disclosed
CN-115872976-A Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of quinoline derivative 中国药科大学 2023-03-31 CN disclosed
EP-1966214-B9 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-13 EP disclosed
EP-1966214-B9 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-13 EP disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 US disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 US disclosed
EP-1966214-B1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-02 EP disclosed
EP-1966214-B1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-02 EP disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 US disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 US disclosed
WO-2007075567-A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-05 WO disclosed
WO-2007075567-A1 TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-05 WO disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed
US-4590194-A 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use STERLING DRUG INC. (US) 1986-05-20 US disclosed
US-4569934-A ANTIANXIETY AGENTS AMERICAN CYANAMID COMPANY (US) 1986-02-11 US disclosed
EP-0029103-B1 6- AND 8-HETEROARYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES AMERICAN CYANAMID COMPANY (US) 1983-05-18 EP disclosed
US-4354026-A 3-Chloro-6-(pyridinyl)-pyridazines STERLING DRUG INC. (US) 1982-10-12 US disclosed
US-4304775-A 3-Hydrazino-6-(pyridinyl) pyridazines and cardiotonic use thereof STERLING DRUG INC. (US) 1981-12-08 US disclosed
EP-0029103-A1 6- and 8-Heteroaryl-1,2,4-triazolo(4,3-b)pyridazines AMERICAN CYANAMID COMPANY (US) 1981-05-27 EP disclosed
US-4260756-A TRANQUILIZERS AMERICAN CYANAMID COMPANY (US) 1981-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS MET, MYC, HGFAC CYP2A6 4419/4885MAPT 3574/4885MEN1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.